Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(7-8):1220–1226. doi: 10.1038/sj.bjc.6690196

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

S J Houston 1,1, T A Plunkett 1,1, D M Barnes 1, P Smith 1, R D Rubens 1, D W Miles 1
PMCID: PMC2362250  PMID: 10098763

Abstract

The present study investigated the interaction between c-erbB2 overexpression and the response to first-line endocrine therapy in patients with advanced breast cancer. The primary tumours of 241 patients who were treated at first relapse with endocrine therapy were assessed for overexpression of c-erbB2 by immunohistochemistry. c-erbB2 was overexpressed in 76 (32%) of primary breast cancers and did not correlate with any other prognostic factor. The overall response to treatment and time to progression were significantly lower in patients with c-erbB2-positive tumours compared to those that were c-erbB2-negative (38% vs 56%, P = 0.02; and 4.1 months vs 8.7 months, P < 0.001, respectively). In multivariate analysis, c-erbB2 status was the most significant predictive factor for a short time to progression (P = 0.0009). In patients with ER-positive primary tumours treated at relapse with tamoxifen (n = 170), overexpression of c-erbB2 was associated with a significantly shorter time to progression (5.5 months vs 11.2 months, P < 0.001). In conclusion, overexpression of c-erbB2 in the primary tumour is an independent marker of relative resistance to first-line endocrine therapy in patients with advanced breast cancer. In patients with ER-positive primary tumours, the overexpression of c-erbB2 defines a subgroup less likely to respond to endocrine therapy. © 1999 Cancer Research Campaign

Keywords: c-erbB2, breast cancer, endocrine therapy, tamoxifen

Full Text

The Full Text of this article is available as a PDF (103.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allred D. C., Clark G. M., Tandon A. K., Molina R., Tormey D. C., Osborne C. K., Gilchrist K. W., Mansour E. G., Abeloff M., Eudey L. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992 Apr;10(4):599–605. doi: 10.1200/JCO.1992.10.4.599. [DOI] [PubMed] [Google Scholar]
  2. Archer S. G., Eliopoulos A., Spandidos D., Barnes D., Ellis I. O., Blamey R. W., Nicholson R. I., Robertson J. F. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer. 1995 Nov;72(5):1259–1266. doi: 10.1038/bjc.1995.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barnes D. M., Lammie G. A., Millis R. R., Gullick W. L., Allen D. S., Altman D. G. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer. 1988 Oct;58(4):448–452. doi: 10.1038/bjc.1988.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barnes D. M., Millis R. R., Beex L. V., Thorpe S. M., Leake R. E. Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer. 1998 Oct;34(11):1677–1682. doi: 10.1016/s0959-8049(98)00149-x. [DOI] [PubMed] [Google Scholar]
  5. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C. C., Dantis L., Sklarin N. T., Seidman A. D., Hudis C. A., Moore J. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996 Mar;14(3):737–744. doi: 10.1200/JCO.1996.14.3.737. [DOI] [PubMed] [Google Scholar]
  6. Borg A., Baldetorp B., Fernö M., Killander D., Olsson H., Rydén S., Sigurdsson H. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 1994 Jun 30;81(2):137–144. doi: 10.1016/0304-3835(94)90194-5. [DOI] [PubMed] [Google Scholar]
  7. Ciocca D. R., Fujimura F. K., Tandon A. K., Clark G. M., Mark C., Lee-Chen G. J., Pounds G. W., Vendely P., Owens M. A., Pandian M. R. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst. 1992 Aug 19;84(16):1279–1282. doi: 10.1093/jnci/84.16.1279. [DOI] [PubMed] [Google Scholar]
  8. Coussens L., Yang-Feng T. L., Liao Y. C., Chen E., Gray A., McGrath J., Seeburg P. H., Libermann T. A., Schlessinger J., Francke U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985 Dec 6;230(4730):1132–1139. doi: 10.1126/science.2999974. [DOI] [PubMed] [Google Scholar]
  9. Gusterson B. A., Gelber R. D., Goldhirsch A., Price K. N., Säve-Söderborgh J., Anbazhagan R., Styles J., Rudenstam C. M., Golouh R., Reed R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992 Jul;10(7):1049–1056. doi: 10.1200/JCO.1992.10.7.1049. [DOI] [PubMed] [Google Scholar]
  10. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  11. Holdaway I. M., Mason B. H., Gibbs E. E., Rajasoorya C., Lethaby A., Hopkins K. D., Evans M. C., Lim T., Schooler B. Seasonal variation in the secretion of mammotrophic hormones in normal women and women with previous breast cancer. Breast Cancer Res Treat. 1997 Jan;42(1):15–22. doi: 10.1023/a:1005743626105. [DOI] [PubMed] [Google Scholar]
  12. Karunagaran D., Tzahar E., Beerli R. R., Chen X., Graus-Porta D., Ratzkin B. J., Seger R., Hynes N. E., Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 1996 Jan 15;15(2):254–264. [PMC free article] [PubMed] [Google Scholar]
  13. Kath R., Höffken K., Otte C., Metz K., Scheulen M. E., Hülskamp F., Seeber S. The neu-oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol. 1993 Aug;4(7):585–590. doi: 10.1093/oxfordjournals.annonc.a058593. [DOI] [PubMed] [Google Scholar]
  14. Kern F. G., Cheville A. L., Liu Y. L. Growth factor receptors and the progression of breast cancer. Semin Cancer Biol. 1990 Oct;1(5):317–328. [PubMed] [Google Scholar]
  15. Kuukasjärvi T., Kononen J., Helin H., Holli K., Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996 Sep;14(9):2584–2589. doi: 10.1200/JCO.1996.14.9.2584. [DOI] [PubMed] [Google Scholar]
  16. Leitzel K., Teramoto Y., Konrad K., Chinchilli V. M., Volas G., Grossberg H., Harvey H., Demers L., Lipton A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol. 1995 May;13(5):1129–1135. doi: 10.1200/JCO.1995.13.5.1129. [DOI] [PubMed] [Google Scholar]
  17. Leitzel K., Teramoto Y., Sampson E., Mauceri J., Langton B. C., Demers L., Podczaski E., Harvey H., Shambaugh S., Volas G. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol. 1992 Sep;10(9):1436–1443. doi: 10.1200/JCO.1992.10.9.1436. [DOI] [PubMed] [Google Scholar]
  18. Newby J. C., Johnston S. R., Smith I. E., Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 1997 Sep;3(9):1643–1651. [PubMed] [Google Scholar]
  19. Niehans G. A., Singleton T. P., Dykoski D., Kiang D. T. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst. 1993 Aug 4;85(15):1230–1235. doi: 10.1093/jnci/85.15.1230. [DOI] [PubMed] [Google Scholar]
  20. O'Malley F. P., Saad Z., Kerkvliet N., Doig G., Stitt L., Ainsworth P., Hundal H., Chambers A. F., Turnbull D. I., Bramwell V. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Hum Pathol. 1996 Sep;27(9):955–963. doi: 10.1016/s0046-8177(96)90224-5. [DOI] [PubMed] [Google Scholar]
  21. Pietras R. J., Arboleda J., Reese D. M., Wongvipat N., Pegram M. D., Ramos L., Gorman C. M., Parker M. G., Sliwkowski M. X., Slamon D. J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995 Jun 15;10(12):2435–2446. [PubMed] [Google Scholar]
  22. Press M. F., Bernstein L., Thomas P. A., Meisner L. F., Zhou J. Y., Ma Y., Hung G., Robinson R. A., Harris C., El-Naggar A. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997 Aug;15(8):2894–2904. doi: 10.1200/JCO.1997.15.8.2894. [DOI] [PubMed] [Google Scholar]
  23. Press M. F., Pike M. C., Chazin V. R., Hung G., Udove J. A., Markowicz M., Danyluk J., Godolphin W., Sliwkowski M., Akita R. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993 Oct 15;53(20):4960–4970. [PubMed] [Google Scholar]
  24. Ravdin P. M., Green S., Dorr T. M., McGuire W. L., Fabian C., Pugh R. P., Carter R. D., Rivkin S. E., Borst J. R., Belt R. J. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992 Aug;10(8):1284–1291. doi: 10.1200/JCO.1992.10.8.1284. [DOI] [PubMed] [Google Scholar]
  25. Rubens R. D., Hayward J. L. Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2922–2924. doi: 10.1002/1097-0142(19801215)46:12+<2922::aid-cncr2820461435>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  26. Saceda M., Grunt T. W., Colomer R., Lippman M. E., Lupu R., Martin M. B. Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. Endocrinology. 1996 Oct;137(10):4322–4330. doi: 10.1210/endo.137.10.8828492. [DOI] [PubMed] [Google Scholar]
  27. Sjögren S., Inganäs M., Lindgren A., Holmberg L., Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998 Feb;16(2):462–469. doi: 10.1200/JCO.1998.16.2.462. [DOI] [PubMed] [Google Scholar]
  28. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  29. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  30. Wright C., Nicholson S., Angus B., Sainsbury J. R., Farndon J., Cairns J., Harris A. L., Horne C. H. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992 Jan;65(1):118–121. doi: 10.1038/bjc.1992.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Yamauchi H., O'Neill A., Gelman R., Carney W., Tenney D. Y., Hösch S., Hayes D. F. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol. 1997 Jul;15(7):2518–2525. doi: 10.1200/JCO.1997.15.7.2518. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES